Opsens Optowire for Fractional Flow Reserve - The O2 Pilot Study (O2)
研究概览
详细说明
Fractional flow reserve (FFR) measurement involves determining the ratio between the maximum achievable blood flow in a diseased coronary artery and the theoretical maximum flow in a normal coronary artery. An FFR of 1.0 is widely accepted as normal. An FFR value lower than 0.75 - 0.80 is generally considered to be associated with myocardial ischemia (MI).
FFR is easily measured during routine coronary angiography by using a pressure wire to calculate the ratio between coronary pressure distal to a coronary artery stenosis and aortic pressure under conditions of maximum myocardial hyperemia. This ratio represents the potential decrease in coronary flow distal to the coronary stenosis.
Over the past decade, FFR measurement has been increasingly used in cardiac catheterization laboratories. It provides a quantitative assessment of the functional severity of a coronary artery stenosis identified during coronary angiography and cardiac catheterization.
Opsens, Inc. has developed a new pressure wire for use in determining FFR in coronary arteries; the OptoWire. The OptoWire is an instrumented guide wire with a fiber optic pressure sensor mounted 3.5 cm proximal to the tip. The Optowire measures blood pressure during diagnostic and/or interventional procedures when used in combination with the OptoMonitor.
The O2 study is a pilot study which aims to provide preliminary experience in human patients with coronary artery disease. The study data will also be used as part of design validation.
The O2 study is a prospective single arm study designed to assess the usability, functionality, and safety of the Optowire and Optomonitor in patients.
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
-
Quebec、加拿大、G1V 4G5
- IUCPQ - Laval Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
Patients with
- Stable angina or,
- Unstable angina pectoris or,
- Atypical chest pain or no chest pain but with suspected ischemia
- At least one moderate lesion in native coronary artery thought to produce ischemia
- Operator and patient agree for procedures
- Patient (> 18 years) has signed a written informed consent prior to procedure
Exclusion Criteria:
- Lesions with angiographic 'haziness' or suspected to contain thrombus
- Post-coronary artery bypass grafting
- Total occlusion
- If use of atherectomy device is indicated
学习计划
研究是如何设计的?
设计细节
- 主要用途:诊断
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Fractional flow reserve
Fractional flow reserve measurement
|
Fractional flow reserve measurement
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Safety and handling assessment of the Optowire
大体时间:Patients will be followed through removal of the OptoWire from percutaneous insertion site and completion of the cardiac catheterization procedure (expected average <1hr)
|
Dedicated questionnaires will be used for such assessment |
Patients will be followed through removal of the OptoWire from percutaneous insertion site and completion of the cardiac catheterization procedure (expected average <1hr)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Comparison of FFR values measured with Optowire vs. with FFR guide wire used in standard practice
大体时间:Patients will be followed through removal of the OptoWire from percutaneous insertion site and completion of the cardiac catheterization procedure (expected average <1hr)
|
In selected cases, the operator may choose to perform FFR measurements using currently approved FFR wires.
Values obtained with standard FFR wires and Optowire may therefore be compared.
|
Patients will be followed through removal of the OptoWire from percutaneous insertion site and completion of the cardiac catheterization procedure (expected average <1hr)
|
合作者和调查者
调查人员
- 首席研究员:Olivier F Bertrand, MD PhD、International Chair on Interventional Cardiology and Transradial Approach
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.